Overview

The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

Status:
Recruiting
Trial end date:
2025-12-02
Target enrollment:
Participant gender:
Summary
The PRINCESS study is a hypothesis-generating, interventional, open-label, non pharmacological trial designed to characterize the translational and clinical implications of the regular assumptions of inulin on Gut Microbiota, circulating cytokines and immune cells dynamics during ICIs +/- chemotherapy on patients affected by R/M HNSCC.
Phase:
N/A
Details
Lead Sponsor:
Fondazione del Piemonte per l'Oncologia
Collaborators:
Ospedale Santa Croce-Carle Cuneo
Università degli Studi di Trento
Treatments:
Nivolumab
Pembrolizumab